Last reviewed · How we verify

Ziv aflibercept

Marashi Eye Clinic · FDA-approved active Small molecule

Ziv aflibercept is a VEGF inhibitor / Antiangiogenic agent Small molecule drug developed by Marashi Eye Clinic. It is currently FDA-approved for Retinal vein occlusion (RVO) with macular edema, Diabetic macular edema (DME), Age-related macular degeneration (AMD). Also known as: ZALTRAP.

Ziv-aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor, binding and sequestering vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit neovascularization.

Ziv-aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor, binding and sequestering vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit neovascularization. Used for Retinal vein occlusion (RVO) with macular edema, Diabetic macular edema (DME), Age-related macular degeneration (AMD).

At a glance

Generic nameZiv aflibercept
Also known asZALTRAP
SponsorMarashi Eye Clinic
Drug classVEGF inhibitor / Antiangiogenic agent
TargetVEGF-A, VEGF-B, PlGF (Placental Growth Factor)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

Ziv-aflibercept functions as a VEGF trap by combining the extracellular domains of VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G1. This construct binds circulating VEGF and PlGF with high affinity, preventing their interaction with endogenous receptors on endothelial cells and thereby suppressing pathological angiogenesis. It is administered as an intravitreal injection for ocular neovascular diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ziv aflibercept

What is Ziv aflibercept?

Ziv aflibercept is a VEGF inhibitor / Antiangiogenic agent drug developed by Marashi Eye Clinic, indicated for Retinal vein occlusion (RVO) with macular edema, Diabetic macular edema (DME), Age-related macular degeneration (AMD).

How does Ziv aflibercept work?

Ziv-aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor, binding and sequestering vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit neovascularization.

What is Ziv aflibercept used for?

Ziv aflibercept is indicated for Retinal vein occlusion (RVO) with macular edema, Diabetic macular edema (DME), Age-related macular degeneration (AMD).

Who makes Ziv aflibercept?

Ziv aflibercept is developed and marketed by Marashi Eye Clinic (see full Marashi Eye Clinic pipeline at /company/marashi-eye-clinic).

Is Ziv aflibercept also known as anything else?

Ziv aflibercept is also known as ZALTRAP.

What drug class is Ziv aflibercept in?

Ziv aflibercept belongs to the VEGF inhibitor / Antiangiogenic agent class. See all VEGF inhibitor / Antiangiogenic agent drugs at /class/vegf-inhibitor-antiangiogenic-agent.

What development phase is Ziv aflibercept in?

Ziv aflibercept is FDA-approved (marketed).

What are the side effects of Ziv aflibercept?

Common side effects of Ziv aflibercept include Conjunctival hemorrhage, Eye pain, Floaters, Intraocular pressure elevation, Endophthalmitis.

What does Ziv aflibercept target?

Ziv aflibercept targets VEGF-A, VEGF-B, PlGF (Placental Growth Factor) and is a VEGF inhibitor / Antiangiogenic agent.

Related